SEC Form 4						
FORM 4	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549			OMB	OMB APPROVAL	
Section 16. Form 4 or Form 5 obligations may continue. See		ENT OF CHANGES IN BENEFICIAL OWNERSHIP ed pursuant to Section 16(a) of the Securities Exchange Act of 1934		OMB Number: 3235-0 Estimated average burden hours per response:		
		or Section 30(h) of the Investment Company Act of 1940				
1. Name and Address of Reporting Person [*] Evans John M.		2. Issuer Name and Ticker or Trading Symbol <u>Beam Therapeutics Inc.</u> [BEAM]	5. Relationship o (Check all applic X Director	able)	on(s) to Issuer 10% Owner	
(Last) (First) C/O BEAM THERAPEUTICS IN	(Middle) C.,	3. Date of Earliest Transaction (Month/Day/Year) 01/31/2024	X Officer below)	X Officer (give title below) CEO		
238 MAIN STREET		4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Ju Line)	oint/Group Filing	(Check Applicable	
(Street)			X Form fi	led by One Repo	rting Person	
CAMBRIDGE MA	02142		Form fi Person	led by More than	One Reporting	

(City) (State) (Zip)

Rule 10b5-1(c) Transaction Indication

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. Х

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 2A. Deemed Execution Date, if any (Month/Day/Year) 2. Transaction Date 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of 6. Ownership Form: Direct (D) or Indirect 7. Nature of 1. Title of Security (Instr. 3) 3. Transaction Indirect Beneficial Securities (Month/Dav/Year) Beneficially Code (Instr 8) Owned Following (I) (Instr. 4) Ownership Reported (Instr. 4) (A) or (D) Transaction(s) v Code Price Amount (Instr. 3 and 4) **S**⁽¹⁾ 1,058,262(3) 01/31/2024 \$25.33(2) Common Stock 60,000 D D By John M. Evans, Common Stock 103,000 III 2018 Ι Irrevocable Trust Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

7. Title and Amount of Securities Underlying Derivative Security 3A. Deemed Execution Date, if any 11. Nature of Indirect Beneficial 1. Title of Derivative 3. Transaction Date 6. Date Exercisable and Expiration Date 8. Price of Derivative 9. Number of 2. Conversion 5. Number of 10. Derivative Securities Transaction Code (Instr. Ownership derivative Security (Instr. 3) (Month/Dav/Year) (Month/Day/Year) Security (Instr. 5) or Exercise Securities Form: Ownership Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) Price of (Month/Day/Year) 8) Beneficially Direct (D) or Indirect (I) (Instr. 4) Derivative (Instr. 3 and 4) Owned (Instr. 4) Following Security Reported Transactio (Instr. 4) nsaction(s) Amount or Number Expiration Date Date v (A) (D) Exercisable Title of Shares Code Stock Option Commor 01/31/2024 (4) \$24.4 155,000 01/31/2034 155,000 \$24.4 155,000 D Α (Right to Stock Buv)

Explanation of Responses:

1. These shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 29, 2023.

2. The price reported is a weighted average price. These shares were sold in multiple transactions ranging from \$24.93 to \$25.92 inclusive. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

3. Includes 283 shares acquired by the Reporting Person under the Beam Therapeutics Inc. Amended and Restated 2019 Employee Stock Purchase Plan on September 30, 2023.

4. This stock option vests in equal monthly installments each month following the date of grant for the subsequent 48 months, subject to the Reporting Person's continued service with BEAM through each vesting date

By: /s/ Christine Bellon, Attorney-in-fact

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).


** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

/AL 3235-0287

0.5



02/02/2024 Date